S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
The Lithium "Lie" (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
The Lithium "Lie" (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
The Lithium "Lie" (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
The Lithium "Lie" (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
The Lithium "Lie" (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
The Lithium "Lie" (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
The Lithium "Lie" (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
The Lithium "Lie" (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
NASDAQ:MBRX

Moleculin Biotech - MBRX Stock Forecast, Price & News

$1.24
-0.01 (-0.80%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.24
$1.27
50-Day Range
$1.06
$1.49
52-Week Range
$0.82
$2.05
Volume
14,756 shs
Average Volume
47,063 shs
Market Capitalization
$35.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Moleculin Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
746.8% Upside
$10.50 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$166,132 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

390th out of 1,026 stocks

Pharmaceutical Preparations Industry

191st out of 504 stocks

MBRX stock logo

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)
The Lithium "Lie"
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China.
Moleculin Announces FDA Fast Track Designation For WP1122
How to Invest in Biotechnology
Moleculin Biotech GAAP EPS of -$0.24
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings
11/11/2021
Today
2/09/2023
Next Earnings (Estimated)
3/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+746.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.76 per share

Miscellaneous

Free Float
27,569,000
Market Cap
$35.50 million
Optionable
Not Optionable
Beta
2.00

Key Executives

  • Walter V. Klemp
    Chairman, President & Chief Executive Officer
  • Jonathan P. Foster
    Chief Financial Officer & Executive Vice President
  • Robert Shepard
    Chief Medical Officer-Annamycin
  • Donald H. Picker
    Chief Scientific Officer
  • Sandra Leta Silberman
    Chief Medical Officer-New Products













MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price forecast for 2023?

1 brokers have issued 1 year price objectives for Moleculin Biotech's shares. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 746.8% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2023?

Moleculin Biotech's stock was trading at $1.06 at the beginning of 2023. Since then, MBRX shares have increased by 17.0% and is now trading at $1.24.
View the best growth stocks for 2023 here
.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 77,200 shares, a decrease of 34.9% from the December 31st total of 118,600 shares. Based on an average daily trading volume, of 101,300 shares, the short-interest ratio is presently 0.8 days. Approximately 0.3% of the company's stock are sold short.
View Moleculin Biotech's Short Interest
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Thursday, November, 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.03. During the same period in the prior year, the company posted ($0.15) earnings per share.

When did Moleculin Biotech's stock split?

Moleculin Biotech's stock reverse split before market open on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.24.

How much money does Moleculin Biotech make?

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $35.50 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 2/9/2023 by MarketBeat.com Staff